Developing circulating tumor cell derived explant models (CDX)

DIVE C, FRESE C, GALVIN M, LALLO A, HODGKINSON C, MORROW C, SIMPSON K, TRAPPANI F, WILLIAMSON S, PRIEST L, GIROTTI MR, MILLER C, BRADY G, MARAIS R, BLACKHALL F.

Conferencia; AACR Annual Meeting 2016; 2016

This session will summarise the expanding utility of ?liquid biopsies? to support patient care. As the sensitivity of circulating tumor DNA (ctDNA) analysis increases, the opportunity for early detection of cancers with a blood test will be explored. Serial analysis of ctDNA to monitor tumor evolution, response and resistance to targeted therapies will be discussed with colorectal cancer the exemplar, a disease where repeat tumor biopsy is challenging. The technical hurdles of circulating tumor cell (CTC) analysis are higher than for ctDNA. Nevertheless, CTCs can provide DNA, RNA and protein data to interrogate the biology of disseminating disease. Focussing on lung cancer, the expansion of CTCs in vivo as CTC derived patient explant models (CDX) will be outlined together with their use as models of progressive disease (where tumor biopsy is rarely obtained) that can facilitate drug development. The session will conclude with an examination of clonal evolution of myeloid malignancies.